Fifth Third Wealth Advisors LLC boosted its stake in Sanofi (NASDAQ:SNY – Free Report) by 27.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission.
3don MSN
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €105.00. The ...
Sanofi (SYN) 43rd Annual J.P. Morgan Healthcare January 14, 2025 12:45 PM ETCompany ParticipantsPaul Hudson - Chief Executive OfficerFrancois-Xavier Roger ...
Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...
“Both companies are ‘houses of brands’, in other words a collection of well-diversified luxury businesses serving multiple ...
Hosted on MSN12d
Sanofi Down 10% in 3 Months: How Should You Play the Stock?Sanofi’s SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend ...
Berenberg Bank analyst Luisa Hector maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €115.00. The ...
The Registered office of the Company has been relocated to Unit 1104 11th Floor Godrej Two Pirojshanagar Eastern Express Highway Vikhroli East Mumbai-400079 Maharashtra India ...
The RTA of the Company has Changed its Name from Link Intime India Private Limited to MUFG Intime India Private Limited ...
SP-0230 is under clinical development by Sanofi and currently in Phase II for Neisseria meningitidis Infections. According to GlobalData, Phase II drugs for Neisseria meningitidis Infections have a 69 ...
Schools with fewer than 3 hires are excluded from the list.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback